Eli Lilly and Company (LLY) Stock Forecast & Price Target

$803.53 -15.85 (-1.93%)

Closing price 10/17/2025 03:59 PM Eastern

Extended Trading

$803.00 -0.53 (-0.07%)

As of 10/17/2025 07:59 PM Eastern

Compare

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
9

Buy
15

Based on 24 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 9 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$939.12
16.87% Upside

According to the 24 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $939.12. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $700.00. The average price target represents a forecasted upside of 16.87% from the current price of $803.53.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

Type	Current Forecast 10/18/24 to 10/18/25	1 Month Ago 9/18/24 to 9/18/25	3 Months Ago 7/20/24 to 7/20/25	1 Year Ago 10/19/23 to 10/18/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	16 Buy rating(s)	17 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$939.12	$939.61	$1,012.56	$986.00
Forecasted Upside	16.87% Upside	23.17% Upside	31.20% Upside	7.42% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.33	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	16.87% Upside	1,356.33% Upside	13.60% Upside
News Sentiment Rating	Positive News See Recent LLY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/16/2025	Guggenheim 3 of 5 stars	Seamus Fernandez Not Rated	Reiterated Rating	Buy	$948.00	+14.74%
10/14/2025	Erste Group Bank 3 of 5 stars		Upgrade	Hold ➝ Buy
10/10/2025	The Goldman Sachs Group 3 of 5 stars		Boost Target	Buy	$876.00 ➝ $879.00	+5.51%
10/9/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Overweight	$925.00	+9.40%
10/8/2025	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C+)
10/3/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,028.00 ➝ $1,023.00	+24.65%
10/1/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target		$700.00 ➝ $800.00	-4.81%
9/17/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$970.00 ➝ $830.00	+8.70%
9/16/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,100.00 ➝ $1,050.00	+40.33%
8/27/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Sell ➝ Hold
Get the Latest News and Ratings for LLY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.
8/17/2025	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Narumi Nakagiri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00	-0.22%
8/17/2025	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
8/14/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
8/11/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,010.00 ➝ $900.00	+40.51%
8/8/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,050.00 ➝ $895.00	+42.63%
8/7/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
8/7/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Market Perform Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$715.00	+11.07%
5/1/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
2/3/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,029.00 ➝ $1,038.00	+27.51%
1/28/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,250.00 ➝ $1,190.00	+47.25%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$997.00	+24.17%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$1,000.00	+27.23%
11/4/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Baker Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
10/31/2024	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Overweight	$1,025.00 ➝ $975.00	+16.30%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$1,100.00	+20.04%
9/5/2024	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
8/9/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$1,001.00 ➝ $1,101.00	+30.36%
6/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$994.00 ➝ $1,015.00	+12.98%
5/14/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$770.00 ➝ $840.00	+11.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:21 AM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 14, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

The current stock price is around $720, reflecting a strong market position and investor confidence in the company's growth potential.
Eli Lilly and Co reported impressive quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health.
The company has shown a remarkable revenue growth of over 37% compared to the same quarter last year, suggesting strong demand for its products.
Institutional investors have been actively increasing their stakes in Eli Lilly and Co, which often signals confidence in the company's future performance.
The company has a high return on equity, demonstrating effective management and profitability, which can be attractive to investors looking for solid returns.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

The stock has a relatively high price-to-earnings (P/E) ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
The company has a significant debt-to-equity ratio, suggesting that it relies heavily on borrowed funds, which could pose risks in a rising interest rate environment.
Despite recent growth, the pharmaceutical industry is highly competitive, and any setbacks in product development or regulatory approvals could negatively impact the company's performance.
Market volatility can affect stock prices, and Eli Lilly and Co's beta indicates that its stock may be less stable compared to the overall market.
Insider ownership is relatively low, which may raise concerns about alignment between management and shareholder interests.

LLY Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $939.12, with a high forecast of $1,190.00 and a low forecast of $700.00.
: 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 9 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.
: According to analysts, Eli Lilly and Company's stock has a predicted upside of 16.87% based on their 12-month stock forecasts.
: Over the previous 90 days, Eli Lilly and Company's stock had 4 upgrades and 3 downgrades by analysts.
: Eli Lilly and Company has been rated by research analysts at Berenberg Bank, Cantor Fitzgerald, Daiwa America, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, DZ Bank, Erste Group Bank, Guggenheim, Hsbc Global Res, HSBC, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days.
: Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating for Eli Lilly and Company is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:LLY) was last updated on 10/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Stock Forecast & Price Target